Selventa CEO David de Graaf Named as one of PharmaVOICE Magazine's "100 Most Inspiring People in the Life Sciences"

Selventa CEO David de Graaf Named as one of PharmaVOICE Magazine's "100 Most Inspiring People in the Life Sciences"

August 9, 2012

CAMBRIDGE, Mass., Aug 09, 2012 (BUSINESS WIRE) -- Selventa(TM), a biomarker discovery company that enables personalized healthcare, today announced that David de Graaf, Selventa's President and Chief Executive Officer, has been selected as one of PharmaVOICE Magazine's "100 Most Inspiring People in the Life Sciences."

The PharmaVOICE 100 were nominated by PharmaVOICE readers who identified individuals they consider to have the greatest influence and positive impact on the life science industry. De Graaf was recognized for his charismatic leadership style as well as the vision of bringing an advanced therapeutic diagnostic for patient stratification through innovative biomarker strategies.

"The unsustainably high failure rate of new drugs is rooted in not knowing enough about the molecular drivers of a patient in the context of a drug," said David de Graaf. "By identifying well characterized biomarkers we better understand the patient/drug interaction, and put patients at the center of the drug development paradigm."

De Graaf added, "At Selventa, we are developing mechanism-based multi-analyte biomarker panels in autoimmune diseases and oncology to effectively identify patients for the most appropriate therapeutic interventions. These innovative new tools will enable pharmaceutical firms to stratify patients based on disease-driving mechanisms, optimize drug development pipeline based on targeted patient sub-populations, and ultimately commercialize successful drugs."

The 2012 annual rankings list, which includes a feature profile on David de Graaf, appears in the July/August issue of PharmaVOICE Magazine and is also available online: http://www.pharmavoice.com/content/digitaledition.html

About Selventa

Founded in 2002 and privately held, Selventa collaborates with partners to match the optimal treatments for the right patients. The company analyzes molecular patient data to identify key disease-driving mechanisms and accelerates the development process to clarify therapeutic and diagnostic decisions through identification and development of biomarkers for patient stratification. Selventa engages in strategic relationships with leading pharmaceutical and life science companies, including clinical research organizations, diagnostic companies, and reference laboratories, to enable personalized healthcare primarily in autoimmune diseases and oncology. For more information, visit www.selventa.com .

SOURCE: Selventa


        
        Selventa 
        Diane H. Song, Ph.D., 617-547-5421 x235 
        dsong@selventa.com 
        or 
        Base Pair Group 
        Constantine Theodoropulos, 617-816-4637 
 
		www.basepairgroup.com            or 
        for Selventa 
        Paul Kidwell, 617-296-3854 
        paulkidwell@comcast.net
        


Copyright Business Wire 2012